WHO recommends dolutegravir as preferred HIV treatment
Извор: Светска здравствена организација – 22.07.2019
Based on new evidence assessing benefits and risks, WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.
DTG is a drug that is more effective, easier to take and has fewer side effects than alternative drugs that are currently used. DTG also has a high genetic barrier to developing drug resistance.
